All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
How significant is the role of MRD status in MM, and how can we best utilize this information?
Featured:
Bruno PaivaThe Multiple Myeloma Hub is pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Bruno Paiva, University of Navarra, Pamplona, ES, answers the question: How significant is the role of minimal residual disease status in myeloma becoming, and how can we best utilize this information?
Bruno Paiva states that minimal residual disease is the most powerful prognostic marker in myeloma and describes the importance of the role of minimal residual disease status in determining the prognosis of multiple myeloma.
How significant is the role of MRD status in MM, and how can we best utilize this information?
Your opinion matters
Which of the following factors is most important to you when selecting a treatment for patients with multiple myeloma?